Venus Remedies Limited, a active public limited company, was established on 15 September 1989 in Chandigarh, Chandigarh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24232CH1989PLC009705. Registered under ROC Roc Chandigarh. it is listed on BSE: 526953 and NSE: VENUSREM. It has an authorized capital of ₹20.00 Cr and a paid-up capital of ₹13.37 Cr.
Formerly known as Venus Glucose Private Limited. It upholds a compliant status. In 2023, it reported revenue of ₹547.84 Cr and a net worth of ₹478.05 Cr. Employing 1,119 professional, Its leadership includes Manu Chaudhary (Whole-Time Director), Akshansh Chaudhary (Whole-Time Director), Jagdish Chander Sharma (Director). Past directors included Rupinder Tewari, Anil Gulati, Akshansh Chaudhary. It holds no open charges and ₹909.48 Cr settled loans. Its latest AGM occurred on 22 August 2025, with the balance sheet filed on 31 March 2025. It is based at Sco 857, 2Nd Floor, C. No. 10 Nac Manimajra, Chandigarh, Chandigarh, 160101.
L24232CH1989PLC009705
009705
15 September 1989
₹20.00 Cr
₹13.37 Cr
Roc Chandigarh
Listed (BSE: 526953, NSE: VENUSREM)
Active
Explore comprehensive insights into Venus Remedies Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manu Chaudhary | Whole-Time Director | 10 Oct 2005 | Current |
| Akshansh Chaudhary | Whole-Time Director | 27 May 2022 | Current |
| Jagdish Chander Sharma | Director | 13 Aug 2024 | Current |
| Npsingh Monga | Director | 29 May 2023 | Current |
| Navdeep Sud | Director | 20 Jun 2020 | Current |
| Ashutosh Jain | Whole-Time Director | 01 May 2007 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 24 May 2019 | Past |
| Pramod Abcsdd | Director | 17 Aug 2009 | Past |
| Pramod Abcsdd | Additional Director | 23 Aug 2022 | Past |
| Pramod Abcsdd | Additional Director | 22 Sep 2024 | Past |
| Pramod Abcsdd | Additional Director | 23 Aug 2023 | Past |
| Pramod Abcsdd | Additional Director | 20 Jun 2020 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Venus Remedies Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.13% decrease. The company also saw a substantial fall in profitability, with a 40.87% decrease in profit. The company's net worth moved up by a moderate rise of 6.37%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Venus Remedies had a promoter holding of 41.76% and a public holding of 58.25%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹9,094,775,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Feb 2015 | Idbi Trusteeship Services Limited | ₹16.57 Cr | Satisfied |
| 31 Mar 2014 | Dena Bank | ₹2.00 Cr | Satisfied |
| 09 Jan 2014 | Andhra Bank | ₹20.00 Cr | Satisfied |
| 09 Jan 2014 | Andhra Bank | ₹5.00 Cr | Satisfied |
| 26 Nov 2013 | Dena Bank | ₹14.50 Cr | Satisfied |
Explore comprehensive loan charge details -
Venus Remedies has a workforce of 1119 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Venus Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venus Remedies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Venus Remedies Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records. was completed.
Progress on Venus Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chandigarh. was documented.
Jagdish Chander Sharma was appointed as a Director was appointed as a Director on 13 Aug 2024 & has been associated with this company since 1 year 3 months . was recorded as a recent event.
Progress on Anil Kumar was appointed as a Director was appointed as a Director on 13 Aug 2024 & has been associated with this company since 1 year 3 months . was documented.
Npsingh Monga was appointed as a Director was appointed as a Director on 29 May 2023 & has been associated with this company since 2 years 5 months . was recorded as a recent event.
Akshansh Chaudhary was appointed as a Whole-time director was appointed as a Whole-time director on 27 May 2022 & has been associated with this company since 3 years 6 months . was recorded as a recent event.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said, These marketing approvals mark a significant milestone in our global expansion strategy. We are looking forward to introducing the entire range of our oncology products in Ukraine in due course, thereby contributing to the advancement of healthcare and making a positive impact on people's lives. .
The GMP certification for the company’s production facilities has added to its portfolio of international approvals from 25 regulators Venus Remedies has been awarded the Good Manufacturing Practices.
When you get approval for your drugs in Israel and Colombia, you know you're a boss in the pharmaceutical game. Docetaxel and cytarabine are now ready to help fight cancer in these countries. Israel and Colombia are both growing markets for medicine, so it's a big win for Venus Remedies. The CEO and President are proud of their team's hard work and excited to bring their drugs to more people..
The CIN of Venus Remedies Limited is L24232CH1989PLC009705.
Venus Remedies Limited is headquartered at Sco 857, 2Nd Floor, C. No. 10 Nac Manimajra, Chandigarh, Chandigarh, 160101.
Venus Remedies Limited was incorporated on 15 September 1989.
The current directors of Venus Remedies Limited are
The primary industry of Venus Remedies Limited is Manufacturing.
Venus Remedies Limited is listed. It is listed on BSE: 526953 and NSE: VENUSREM.
The authorized capital of Venus Remedies Limited is ₹20.00 Cr, and the paid-up capital is ₹13.37 Cr.
The compliance status of Venus Remedies Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX